is the fda going to ban compounded semaglutide FDA's Decision Compounds: What You Need to Know fda ban on semaglutide compounding

Dementia risk is complex, and GLP-1 therapy has risks, contraindications, and monitoring needs

Reinhardt C, Reigstad CS, Backhed F

Most protocols run weekly, with some clinics using twice-weekly or every-other-week schedules depending on the formulation and the patient

Temporary hair thinning affects approximately 3-4% of users, typically appearing 3-6 months after starting treatment

Semaglutide is a GLP-1 receptor agonist that works by: Reducing appetite Increasing fullness Slowing gastric emptying Improving insulin sensitivity Brand-name versions include: Ozempic (commonly used off-label for weight loss) Wegovy (FDA-approved specifically for chronic weight management) Semaglutide has one of the largest bodies of clinical evidence in obesity medicine

2.4 mg = 0.48 ml = 48 units